Referral: The General Court of the European Union validates the renewed reading of Article 22 of the EU Merger Regulation adopted by the European Commission (Illumina)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. The Illumina / Grail case is still in the news, and for good reason: it is the first case in which the European Commission [hereinafter the "Commission"] has accepted a referral request based on Article 22 of Regulation (EC) No. 139/2004 of January 20, 2004 on the control of concentrations between undertakings [the "Merger Regulation"] in its new version. As a reminder, on September 20, 2020, Illumina - a genetic and genomic analysis solutions company - entered into an agreement to acquire sole control of Grail, a developer of blood-based early cancer detection tests [hereinafter the "Transaction"]. As the turnover of the companies concerned did not

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Olivier Billard, Quentin Colombier, Referral: The General Court of the European Union validates the renewed reading of Article 22 of the EU Merger Regulation adopted by the European Commission (Illumina), 13 July 2022, Concurrences N° 4-2022, Art. N° 109458, pp. 97-101

Visites 80

All reviews